Research programme: cancer therapeutics - Rhizen/Incozen

Drug Profile

Research programme: cancer therapeutics - Rhizen/Incozen

Alternative Names: RP-10107

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incozen Therapeutics; Rhizen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glutaminase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Apr 2016 Research programme: cancer therapeutics - Rhizen/Incozen is available for licensing as of 28 Apr 2016.
  • 06 Dec 2013 A lead candidate from this programme has entered clinical development
  • 12 Jun 2013 Preclinical trials in Haematological malignancies in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top